noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

City of Fort Worth, TX

Compliance for conservation: No-cost residential irrigation assessment
NRCM - Natural Resources Council[...]

Conservation Groups File Appeal Urging CMP Compliance with Mature[...]
ETA - Employment and Training[...]

US departments of Labor, Agriculture announce effort to streamline job[...]

Healthcare

Spero Therapeutics Inc.

12/19/2025 | Press release | Distributed by Public on 12/19/2025 07:26

Material Event (Form 8-K)

Item 8.01.

Other Events.

On December 19, 2025, Spero Therapeutics, Inc. (the "Company") announced that its tebipenem HBr development partner, GlaxoSmithKline Intellectual Property (No. 3) Limited ("GSK"), filed a New Drug Application ("NDA") resubmission to the U.S. Food and Drug Administration for tebipenem HBr, an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis. The NDA submission triggers a $25 million milestone payment to the Company under the Company's License Agreement, as amended, with GSK, which is expected to be received in the first quarter of 2026.

Spero Therapeutics Inc. published this content on December 19, 2025, and is solely responsible for the information contained herein. Distributed via Edgar on December 19, 2025 at 13:26 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]